Cargando…

Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States

BACKGROUND: The efficacy and safety of eptinezumab for preventive migraine treatment in adults have been demonstrated in multiple, large-scale clinical trials. This non-interventional, retrospective, observational chart review was conducted to examine patient response to eptinezumab 100 mg or 300 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Starling, Amaal J., Kymes, Steven, Asher, Divya, Soni-Brahmbhatt, Seema, Karnik-Henry, Meghana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116681/ https://www.ncbi.nlm.nih.gov/pubmed/37081405 http://dx.doi.org/10.1186/s12883-023-03204-8

Ejemplares similares

Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Eptinezumab for migraine
Publicado: (2022)

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
por: Cowan, Robert P., et al.
Publicado: (2022)

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
por: Apelian, Rami, et al.
Publicado: (2022)

Characterization of the changes in supine blood pressure with long‐term use of droxidopa in patients with neurogenic orthostatic hypotension
por: Hewitt, L. Arthur, et al.
Publicado: (2021)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
por: Charleston, Larry, et al.
Publicado: (2023)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

A Review of Eptinezumab Use in Migraine
por: Datta, Abhigyan, et al.
Publicado: (2021)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
por: Bader, Yazan, et al.
Publicado: (2023)

Eptinezumab for migraine prevention in patients 50 years or older
por: Martin, Vincent, et al.
Publicado: (2022)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
por: Lipton, Richard B., et al.
Publicado: (2020)

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
por: Baker, Brian, et al.
Publicado: (2021)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States
por: Mørup, Michael Frank, et al.
Publicado: (2020)

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

The eptinezumab:CGRP complex structure – the role of conformational changes in binding stabilization
por: David, Laurent, et al.
Publicado: (2021)

Effect of Levothyroxine on Kidney Function in Chronic Kidney Disease with Subclinical Hypothyroidism in US Veterans: A Retrospective Observational Cohort Study
por: Hennessey, James V., et al.
Publicado: (2020)

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
por: Baker, Brian, et al.
Publicado: (2020)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial
por: Li, Xue-Ning, et al.
Publicado: (2023)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

MON-LB099 The Association between Switching from Synthroid(®) and Clinical Outcomes: Retrospective Analysis of a US Database
por: Espillat, Ramon, et al.
Publicado: (2019)

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
por: Ashina, Messoud, et al.
Publicado: (2020)

Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial
por: Ray, Jason Charles, et al.
Publicado: (2022)

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
por: Blumenfeld, Andrew, et al.
Publicado: (2022)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2022)

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020)

Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials
por: Yan, Zeya, et al.
Publicado: (2021)

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

The Association Between Switching from Synthroid(®) and Clinical Outcomes: US Evidence from a Retrospective Database Analysis
por: Hennessey, James V., et al.
Publicado: (2020)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
por: McAllister, Peter, et al.
Publicado: (2022)

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
por: Chiang, Chia-Chun, et al.
Publicado: (2017)

Treatment-Refractory Headache in the Setting of COVID-19 Pneumonia: Migraine or Meningoencephalitis? Case Report
por: Arca, Karissa N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h602du80cttk1t6sk1c3nssncg